Surfactants: Their critical role in enhancing drug delivery to the lungs

Therapeutic Delivery

Volumn 2, Issue 5, 2011, Pages 623-641

  Morales, Javier O ^a   Peters, Jay I ^b   Williams, Robert O ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; BUDESONIDE; CHOLIC ACID; CYCLOSPORIN A; DEOXYCHOLIC ACID; DILAUROYLPHOSPHATIDYLCHOLINE; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DIPALMITOYLPHOSPHATIDYLCHOLINE; DIPALMITOYLPHOSPHATIDYLGLYCEROL; DISTEAROYLPHOSPHATIDYLCHOLINE; FUROSEMIDE; GLYCOCHOLIC ACID; GLYCODEOXYCHOLIC ACID; LINOLEIC ACID; LIPOSOME; LUNG SURFACTANT; OCTADECYLAMINE; OLEIC ACID; OLEYL ALCOHOL; PALMITOLEIC ACID; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID; POLOXAMER; POLYSORBATE 80; SORBITAN STEARATE; SORBITAN TRIOLEATE; SURFACTIN; TAUROCHOLIC ACID; TOBRAMYCIN; UNINDEXED DRUG;

AREA UNDER THE CURVE; BASEMENT MEMBRANE; CAPILLARY ENDOTHELIUM; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; HUMAN; LUNG ALVEOLUS EPITHELIUM; LUNG DISEASE; LUNG INTERSTITIUM; MAXIMUM PLASMA CONCENTRATION; METERED DOSE INHALER; NEBULIZER; NONHUMAN; POWDER INHALER; PRIORITY JOURNAL; REVIEW;

EID: 79956132295     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.11.15     Document Type: Review

References (117)

1. Hoover JL, Rush BD, Wilkinson KF et al. Peptides are better absorbed from the lung than the gut in the rat. Pharm. Res. 9(8), 1103-1106 (1992).
2. Banga AK. Pulmonary and other mucosal delivery of therapeutics peptides and proteins. In: Therapeutic Peptides and Proteins Formulation, Processing, and Delivery Systems (2nd Edition). CRC/Taylor & Francis, Boca Raton, FL, USA 291-326 (2006).
3. Patton JS. Mechanisms of macromolecule absorption by the lungs. Adv. Drug Deliv. Rev. 19(1), 3-36 (1996). (Pubitemid 26167852)
4. Thurlbeck WM. The internal surface area of nonemphysematous lungs. Am. Rev. Respir. Dis. 95(5), 765-773 (1967).
5. Weibel ER. Morphological basis of alveolar-capillary gas exchange. Physiol. Rev. 53(2), 419 (1973).
6. Agu U, Ugwoke I, Armand M, Kinget R, Verbeke N. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir. Res. 2(4), 198 (2001). Excellent article on the mechanisms for drug absorption in the lungs with a detailed description of the lung physiology.
7. Clark AR, Shire SJ. Formulation of proteins for pulmonary drug delivery. In:Protein Formulation and Delivery McNally EJ (Ed.). M Dekker, NY, USA 201-234 (2000).
8. Groneberg DA, Witt C, Wagner U, Chung KF, Fischer A. Fundamentals of pulmonary drug delivery. Respir. Med. 97(4), 382-387 (2003). (Pubitemid 36410606)
9. Yu J, Chien YW. Pulmonary drug delivery: Physiologic and mechanistic aspects. Crit. Rev. Ther. Drug Carrier Syst. 14(4), 395 (1997).
10. Newman SP, Chan HK. In vitro/in vivo comparisons in pulmonary drug delivery. J. Aerosol Med. Pulm. Drug Deliv. 21(1), 77-84 (2008).
11. Taylor KMG, McCallion ONM. Ultrasonic nebulisers for pulmonary drug delivery. Int. J. Pharm. 153(1), 93-104 (1997). (Pubitemid 27283337)
12. Dennis J, Nerbrink O. New nebulizer technology. In:Drug Delivery to the Lung Bisgaard H, O'Callaghan C, Smaldone GC (Eds). Marcel Dekker, NY, USA (2002).
13. Rubin BK, Fink JB. Optimizing aerosol delivery by pressurized metered-dose inhalers. Respir. care 50(9), 1191-1200 (2005).
14. McDonald KJ, Martin GP. Transition to CFC-free metered dose inhalers - into the new millennium. Int. J. Pharm. 201(1), 89-107 (2000). (Pubitemid 30364973)
15. Bell J, Newman S. The rejuvenated pressurised metered dose inhaler. Expert Opin. Drug Deliv. 4(3), 215-234 (2007). (Pubitemid 46767625)
16. Newman SP, Busse WW. Evolution of dry powder inhaler design, formulation, and performance. Respir. Med. 96(5), 293-304 (2002).
17. Atkins PJ. Dry powder inhalers: An overview. Respir. Care 50(10), 1304-1312 (2005). (Pubitemid 46173313)
18. Ilowite JS, Gorvoy JD, Smaldone GC. Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am. Rev. Respir. Dis. 136(6), 1445-1449 (1987). (Pubitemid 18030280)
19. Collis GG, Cole CH, Le Souef PN. Dilution of nebulised aerosols by air entrainment in children. Lancet 336(8711), 341-343 (1990). (Pubitemid 20264149)
20. Köhler E, Sollich V, Schuster-Wonka R, Hühnerbein J. Lung deposition in cystic fibrosis patients using an ultrasonic or a jet nebulizer. J. Aerosol Med. 16(1), 37-46 (2003). (Pubitemid 36457652)
21. Le Brun PPH, de Boer AH, Gjaltema D et al. Inhalation of tobramycin in cystic fibrosis: Part 2: Optimization of the tobramycin solution for a jet and an ultrasonic nebulizer. Int. J. Pharm. 189(2), 215-225 (1999). (Pubitemid 29481757)
22. Geller DE, Pitlick WH, Nardella PA, Tracewell WG, Ramsey BW. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 122(1), 219-226 (2002). (Pubitemid 34754166)
23. Dhand R. Nebulizers that use a vibrating mesh or plate with multiple apertures to generate aerosol. Respir. Care 47(12), 1406-1418 (2002).
24. Byrne NM, Keavey PM, Perry JD, Gould FK, Spencer DA. Comparison of lung deposition of colomycin using the HaloLite and the Pari LC Plus nebulisers in patients with cystic fibrosis. Arch. Dis. Child. 88(8), 715-718 (2003). (Pubitemid 36930311)
25. Newman SP, Flora M, Hirst PH et al. Pharmacoscintigraphy of TOBI in the PARI LC PLUS, and the AeroDose inhaler. J. Aerosol Med. 14, 388 (2001).
26. Coates AL, Green M, Leung K et al. The challenges of quantitative measurement of lung deposition using 99mTc-DTPA from delivery systems with very different delivery times. J. Aerosol Med. 20(3), 320-330 (2007). (Pubitemid 47463185)
27. ®) System. J. Aerosol Med. 20, 192-193 (2007).
28. Meltzer EO. Formulation considerations of intranasal corticosteroids for the treatment of allergic rhinitis. Ann. Allergy, Asthma Immunol. 98(1), 12-21 (2007). (Pubitemid 46106153)
29. Newman S. Principles of metered-dose inhaler design. Respir. Care 50(9), 1177-1190 (2005).
30. Crowder TM, Louey MD, Sethuraman VV, Smyth HDC, Hickey AJ. 2001: An odyssey in inhaler formulations and design. Pharm. Technol. 25(7), 99-113 (2001).
31. Olmsted SS, Padgett JL, Yudin AI et al. Diffusion of macromolecules and virus-like particles in human cervical mucus. Biophys. J. 81(4), 1930-1937 (2001). (Pubitemid 32917145)
32. Saltzman W, Radomsky M, Whaley K, Cone R. Antibody diffusion in human cervical mucus. Biophys. J. 66(2), 508-515 (1994). (Pubitemid 24058469)
33. Lai SK, O'Hanlon DE, Harrold S et al. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc. Natl Acad. Sci. USA 104(5), 1482-1487 (2007). (Pubitemid 46214616)
34. DeFelippis MR, Sukumar M, Rajagopalan N. Peptides and proteins: Non-invasive delivery. In:Encyclopedia of Pharmaceutical Technology (3rd Edition). Swarbrick J (Ed.). Informa Healthcare, NY, USA, 2692-2712 (2006).
35. Hussain A, Arnold JJ, Khan MA, Ahsan F. Absorption enhancers in pulmonary protein delivery. J. Control. Release 94(1), 15-24 (2004). Comprehensive review of the various absorption enhancers utilized in lung-delivery formulations. (Pubitemid 37542374)
36. Myers MA, Thomas DA, Straub L et al. Pulmonary effects of chronic exposure to liposome aerosols in mice. Exp. Lung Res. 19(1), 1-19 (1993). (Pubitemid 23042785)
37. Thomas D, Myers M, Wichert B, Schreier H, Gonzalez-Rothi R. Acute effects of liposome aerosol inhalation on pulmonary function in healthy human volunteers. Chest 99(5), 1268-1270 (1991).
38. Waldrep J, Knight C, Black M et al. Pulmonary delivery of beclomethasone liposome aerosol in volunteers. Chest 111(2), 316-323 (1997). (Pubitemid 27096944)
39. Possmayer F, Nag K, Rodriguez K, Qanbar R, Schürch S. Surface activity in vitro: Role of surfactant proteins. Comp. Biochem. Physiol. A Mol. Integr. Physiol. 129(1), 209-220 (2001). (Pubitemid 32455718)
40. FDA Guidance for Industry. Guidance on the Labeling of Certain Uses of Lecithin Derived from Soy Under Section 403(w) of the Federal Food, Drug, and Cosmetic Act. US FDA, Rockville, MD, USA (2006).
41. Rawat M, Singh D, Saraf S, Saraf S. Lipid carriers: A versatile delivery vehicle for proteins and peptides. Yakugaku Zasshi 128(2), 269-280 (2008). (Pubitemid 351237899)
42. Sebti T, Amighi K. Preparation and in vitro evaluation of lipidic carriers and fillers for inhalation. Eur. J. Pharm. Biopharm. 63(1), 51-58 (2006).
43. Desai TR, Hancock REW, Finlay WH. Delivery of liposomes in dry powder form: Aerodynamic dispersion properties. Eur. J. Pharm. Sci. 20(4-5), 459-467 (2003). (Pubitemid 37491439)
44. Sebti T, Pilcer G, Van Gansbeke B et al. Pharmacoscintigraphic evaluation of lipid dry powder budesonide formulations for inhalation. Eur. J. Pharm. Biopharm. 64(1), 26-32 (2006). (Pubitemid 44142238)
45. ™. Respir. Med. 96(6), 389-396 (2002). (Pubitemid 36443154)
46. Vanbever R, Mintzes JD, Wang J et al. Formulation and physical characterization of large porous particles for inhalation. Pharm. Res. 16(11), 1735-1742 (1999). (Pubitemid 29530407)
47. Wang J, Ben-Jebria A, Edwards D. Inhalation of estradiol for sustained systemic delivery. J. Aerosol Med. 12(1), 27-36 (1999). (Pubitemid 29109297)
48. Bosquillon C, Préat V, Vanbever R. Pulmonary delivery of growth hormone using dry powders and visualization of its local fate in rats. J. Control. Release 96(2), 233-244 (2004). (Pubitemid 38481506)
49. Lindmark T, Kimura Y, Artursson P. Absorption enhancement through intracellular regulation of tight junction permeability by medium chain fatty acids in Caco-2 cells. J. Pharm. Exper. Ther. 284(1), 362-369 (1998). (Pubitemid 28109567)
50. Codrons V, Vanderbist F, Ucakar B, Preat V, Vanbever R. Impact of formulation and methods of pulmonary delivery on absorption of parathyroid hormone (1-34) from rat lungs. J. Pharm. Sci. 93(5), 1241-1252 (2004). (Pubitemid 38529697)
51. Mitra R, Pezron I, Li Y, Mitra AK. Enhanced pulmonary delivery of insulin by lung lavage fluid and phospholipids. Int. J. Pharm. 217(1-2), 25-31 (2001). (Pubitemid 32268630)
52. Ungaro F, Giovino C, Coletta C et al. Engineering gas-foamed large porous particles for efficient local delivery of macromolecules to the lung. Eur. J. Pharm. Sci. 41(1), 60-70 (2010).
53. Dellamary L, Tarara T, Smith D et al. Hollow porous particles in metered dose inhalers. Pharm. Res. 17(2), 168-174 (2000). (Pubitemid 30158365)
54. ® powder. Pharm. Res. 19(5), 689-695 (2002). (Pubitemid 34553679)
55. Newhouse M, Hirst P, Duddu S et al. Inhalation of a dry powder tobramycin pulmosphere formulation in healthy volunteers. Chest 124(1), 360-366 (2003). (Pubitemid 36851374)
56. Hadinoto K, Phanapavudhikul P, Kewu Z, Tan RB. Dry powder aerosol delivery of large hollow nanoparticulate aggregates as prospective carriers of nanoparticulate drugs: Effects of phospholipids. Int. J. Pharm. 333(1-2), 187-198 (2007). (Pubitemid 46283279)
57. Grenha A, Seijo B, Remuñán-López C. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur. J. Pharm. Sci. 25(4-5), 427-437 (2005). (Pubitemid 40853870)
58. Hadinoto K, Phanapavudhikul P, Kewu Z, Tan RBH. Novel formulation of large hollow nanoparticles aggregates as potential carriers in inhaled delivery of nanoparticulate drugs. Ind. Eng. Chem. Res. 45(10), 3697-3706 (2006). Report on the development of large hollow nanoparticle aggregates and in vitro characterization. (Pubitemid 43812807)
59. Tsapis N, Bennett D, Jackson B, Weitz DA, Edwards DA. Trojan particles: Large porous carriers of nanoparticles for drug delivery. Proc. Natl Acad. Sci. USA 99(19), 12001-12005 (2002).
60. Evora C, Soriano I, Rogers RA et al. Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: The effect of 1,2-dipalmitoylphosphatidylcholine. J. Control. Release 51(2-3), 143-152 (1998). (Pubitemid 28252865)
61. Jones BG, Dickinson PA, Gumbleton M, Kellaway IW. Lung surfactant phospholipids inhibit the uptake of respirable microspheres by the alveolar macrophage NR8383. J. Pharm. Pharmacol. 54, 1065-1072 (2002).
62. Van Oort M, Sacchetti M. Spray-drying and supercritical fluid particle generation techniques. In:Inhalation Aerosols: Physical and Biological Basis for Therapy (2nd Edition). Hickey AJ (Ed.). Informa Healthcare, Hoboken, NJ, USA 307-346 (2007).
63. Bosquillon C, Lombry C, Préat V, Vanbever R. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. J. Control. Release 70(3), 329-339 (2001). (Pubitemid 32155456)
64. Malik S, Washington C, Purewal TS. Solution and adsorption behavior of lecithin surfactants in CFC suspensions: A light scattering study in aerosol propellants. Int. J. Pharm. 186(1), 63-69 (1999). (Pubitemid 29397523)
65. Saso Y, Kondo S, Seki T, Morimoto K. Formulation design and pharmaceutical evaluation of an HFA 227-based furosemide metered dose inhaler. STP Pharma Sci. 14(2), 135-140 (2004). Report on the use of lecithin as a coating agent of furosemide particles to be dispersed in an hydrofluoroalkane propellant-based metered dose inhaler. (Pubitemid 38506441)
66. Tarara T, Hartman M, Gill H, Kennedy A, Weers J. Characterization of suspension-based metered dose inhaler formulations composed of spray-dried budesonide microcrystals dispersed in HFA-134a. Pharm. Res. 21(9), 1607-1614 (2004). (Pubitemid 41184391)
67. Saso Y, Seki T, Fukuchi R, Chono S, Morimoto K. Effect of lecithin coating on the pulmonary absorption of furosemide in rats. Bio. Pharm. Bull. 29(7), 1445-1448 (2006).
68. Sommerville ML, Cain JB, Johnson CS Jr, Hickey AJ. Lecithin inverse microemulsions for the pulmonary delivery of polar compounds utilizing dimethylether and propane as propellants. Pharm. Devel. Technol. 5(2), 219-230 (2000). (Pubitemid 30247103)
69. Hiranita T, Nakamura S, Kawachi M et al. Miscibility behavior of dipalmitoylphosphatidylcholine with a single-chain partially fluorinated amphiphile in Langmuir monolayers. J. Colloid Interface Sci. 265(1), 83-92 (2003). (Pubitemid 36961415)
70. Courrier HM, Krafft MP, Butz N et al. Evaluation of cytotoxicity of new semi-fluorinated amphiphiles derived from dimorpholinophosphate. Biomaterials 24(4), 689-696 (2003). (Pubitemid 35346397)
71. Courrier H, Pons F, Lessinger J et al. In vivo evaluation of a reverse water-in-fluorocarbon emulsion stabilized with a semifluorinated amphiphile as a drug delivery system through the pulmonary route. Int. J. Pharm. 282(1-2), 131-140 (2004). (Pubitemid 39178490)
72. Saso Y, Seki T, Chono S, Morimoto K. An HFA 227-based metered dose inhaler containing furosemide coated with lecithin. J. Drug Deliv. Sci. Technol. 16(2), 147-150 (2006).
73. Bi R, Zhang N. Liposomes as a carrier for pulmonary delivery of peptides and proteins. J. Biomed. Nanotechnol. 3(4), 332-341 (2007). (Pubitemid 351877136)
74. Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int. J. Pharm. 392(1-2), 1-19 (2010). Comprehensive survey of excipients used in the formulations of nebulizers, metered dose inhalers and dry powder inhalers with major focus on the latter.
75. Iacono A, Smaldone G, Keenan R et al. Dose-related reversal of acute lung rejection by aerosolized cyclosporine. Am. J. Respir. Crit. Care Med. 155(5), 1690-1698 (1997). (Pubitemid 27216679)
76. Mitruka SN, Pham SM, Zeevi A et al. Aerosol cyclosporine prevents acute allograft rejection in experimental lung transplantation. J. Thorac. Cardiovasc. Surg. 115(1), 28-37 (1998). (Pubitemid 28082144)
77. Letsou GV, Safi HJ, Reardon MJ et al. Pharmacokinetics of liposomal aerosolized cyclosporine A for pulmonary immunosuppression. Ann. Thorac. Surg. 68(6), 2044-2048 (1999). (Pubitemid 30027822)
78. Lo Y, Tsai J, Kuo J. Liposomes and disaccharides as carriers in spray-dried powder formulations of superoxide dismutase. J. Control. Release 94(2-3), 259-272 (2004). (Pubitemid 38117138)
79. Chono S, Fukuchi R, Seki T, Morimoto K. Aerosolized liposomes with dipalmitoyl phosphatidylcholine enhance pulmonary insulin delivery. J. Control. Release 137(2), 104-109 (2009).
80. Kobayashi S, Kondo S, Juni K. Study on pulmonary delivery of salmon calcitonin in rats: Effects of protease inhibitors and absorption enhancers. Pharm. Res. 11(9), 1239-1243 (1994). (Pubitemid 24287400)
81. Kobayashi S, Kondo S, Juni K. Pulmonary delivery of salmon calcitonin dry powders containing absorption enhancers in rats. Pharm. Res. 13(1), 80-83 (1996). (Pubitemid 26076300)
82. Zaru M, Mourtas S, Klepetsanis P, Fadda AM, Antimisiaris SG. Liposomes for drug delivery to the lungs by nebulization. Eur. J. Pharm. Biopharm. 67(3), 655-666 (2007). (Pubitemid 47576612)
83. Bridges PA, Taylor KM. An investigation of some of the factors influencing the jet nebulisation of liposomes. Int. J. Pharm. 204(1-2), 69-79 (2000).
84. Gürsoy A, Kut E, ÖzkIrImlI S. Co-encapsulation of isoniazid and rifampicin in liposomes and characterization of liposomes by derivative spectroscopy. Int. J. Pharm. 271(1-2), 115-123 (2004).
85. Zaru M, Manca M, Fadda AM, Antimisiaris SG. Chitosan-coated liposomes for delivery to lungs by nebulisation. Colloids Surf. B Biointerfaces 71(1), 88-95 (2009).
86. Darwis Y, Kellaway IW. Nebulisation of rehydrated freeze-dried beclomethasone dipropionate liposomes. Int. J. Pharm. 215(1-2), 113-121 (2001). (Pubitemid 32206609)
87. Smola M, Vandamme T, Sokolowski A. Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases. Int. J. Nanomedicine 3(1), 1-19 (2008). (Pubitemid 351517072)
88. Nicolazzo JA, Reed BL, Finnin BC. Buccal penetration enhancers - how do they really work? J. Control. Release 105(1-2), 1-15 (2005). (Pubitemid 40805471)
89. Johansson F, Hjertberg E, Eirefelt S, Tronde A, Hultkvist Bengtsson U. Mechanisms for absorption enhancement of inhaled insulin by sodium taurocholate. Eur. J. Pharm. Sci. 17(1-2), 63-71 (2002). (Pubitemid 35287172)
90. Heinemann L, Klappoth W, Rave K et al. Intra-individual variability of the metabolic effect of inhaled insulin together with an absorption enhancer. Diabetes Care 23(9), 1343-1347 (2000).
91. Morimoto K, Uehara Y, Iwanaga K, Kakemi M. Effects of sodium glycocholate and protease inhibitors on permeability of TRH and insulin across rabbit trachea. Pharm. Acta Helv. 74(4), 411-415 (2000). (Pubitemid 30227328)
92. Yamamoto A, Okumura S, Fukuda Y et al. Improvement of the pulmonary absorption of (Asu1,7)-eel calcitonin by various absorption enhancers and their pulmonary toxicity in rats. J. Pharm. Sci. 86(10), 1144-1147 (1997). (Pubitemid 27430920)
93. Mesiha MS, Ponnapula S, Plakogiannis F. Oral absorption of insulin encapsulated in artificial chyles of bile salts, palmitic acid and [a]-tocopherol dispersions. Int. J. Pharm. 249(1-2), 1-5 (2002). (Pubitemid 35333427)
94. Komada F, Iwakawa S, Yamamoto N, Sakakibara H, Okumura K. Intratracheal delivery of peptide and protein agents: Absorption from solution and dry powder by rat lung. J. Pharm. Sci. 83(6), 863-867 (1994). (Pubitemid 24233766)
95. Erjavec Z, Woolthuis GMH, Vries-Hospers HG et al. Tolerance and efficacy of amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in haematological patients. Eur. J. Clin. Microbiol. Infect. Dis. 16(5), 364-368 (1997). (Pubitemid 27271824)
96. Drew RH, Dodds Ashley E, Benjamin DK Jr et al. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 77(2), 232-237 (2004). (Pubitemid 38155752)
97. Wollmer P, Bäckström K, Zhao H, Nilsson PG, Jonson B. Surface active agents as enhancers of alveolar absorption. Pharm. Res. 17(1), 38-41 (2000). (Pubitemid 30121097)
98. Freeman DJ, Niven RW. The influence of sodium glycocholate and other additives on the in vivo transfection of plasmid DNA in the lungs. Pharm. Res. 13(2), 202-209 (1996). (Pubitemid 26072139)
99. Li HY, Seville PC, Williamson IJ, Birchall JC. The use of absorption enhancers to enhance the dispersibility of spray-dried powders for pulmonary gene therapy. J. Gene Med. 7(8), 1035-1043 (2005). Investigation of the influence of absorption enhancers in the dispersion properties of spray-dried powders and their biological activity in vitro. (Pubitemid 41195065)
100. Ungaro F, De Rosa G, Miro A, Quaglia F, La Rotonda MI. Cyclodextrins in the production of large porous particles: Development of dry powders for the sustained release of insulin to the lungs. Eur. J. Pharm. Sci. 28(5), 423-432 (2006). (Pubitemid 44038350)
101. Niven RW, Byron PR. Solute absorption from the airways of the isolated rat lung. II. Effect of surfactants on absorption of fluorescein. Pharm. Res. 7(1), 8-13 (1990). (Pubitemid 20115791)
102. Takatsuka S, Morita T, Horikiri Y, Yamahara H, Saji H. Absorption enhancement of poorly absorbed hydrophilic compounds from various mucosal sites by combination of mucolytic agent and non-ionic surfactant. Int. J. Pharm. 338(1-2), 87-93 (2007). (Pubitemid 46777222)
103. Hosoya K, Kubo H, Natsume H et al. The structural barrier of absorptive mucosae: Site difference of the permeability of fluorescein isothiocyanate- labelled dextran in rabbits. Biopharm. Drug Dispos. 14(8), 685-695 (1993). (Pubitemid 23326731)
104. Yamamoto A, Iseki T, Ochi-Sugiyama M et al. Absorption of water-soluble compounds with different molecular weights and [Asu1.7]-eel calcitonin from various mucosal administration sites. J. Control. Release 76(3), 363-374 (2001). (Pubitemid 32913443)
105. Machida M, Hayashi M, Awazu S. The effects of absorption enhancers on the pulmonary absorption of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in rats. Biol. Pharm. Bull. 23(1), 84-86 (2000). (Pubitemid 30077799)
106. Okumura K, Iwakawa S, Yoshida T, Seki T, Komada F. Intratracheal delivery of insulin absorption from solution and aerosol by rat lung. Int. J. Pharm. 88(1-3), 63-73 (1992). (Pubitemid 23000409)
107. McConville JT, Overhoff KA, Sinswat P et al. Targeted high lung concentrations of itraconazole using nebulized dispersions in a murine model. Pharm. Res. 23(5), 901-911 (2006). (Pubitemid 43781398)
108. Vaughn JM, Wiederhold NP, McConville JT et al. Murine airway histology and intracellular uptake of inhaled amorphous itraconazole. Int. J. Pharm. 338(1-2), 219-224 (2007). (Pubitemid 46777243)
109. Fiegel J, Fu J, Hanes J. Poly(ether-anhydride) dry powder aerosols for sustained drug delivery in the lungs. J. Control. Release 96(3), 411-423 (2004). (Pubitemid 38553920)
110. Fu J, Fiegel J, Krauland E, Hanes J. New polymeric carriers for controlled drug delivery following inhalation or injection. Biomaterials 23(22), 4425-4433 (2002).
111. Rawat A, Majumder Q, Ahsan F. Inhalable large porous microspheres of low molecular weight heparin: In vitro and in vivo evaluation. J. Control. Release 128(3), 224-232 (2008).
112. Steckel H, Brandes HG. A novel spray-drying technique to produce low density particles for pulmonary delivery. Int. J. Pharm. 278(1), 187-195 (2004). (Pubitemid 38670449)
113. Wang L, Zhang Y, Tang X. Characterization of a new inhalable thymopentin formulation. Int. J. Pharm. 375(1-2), 1-7 (2009).
114. Adler M, Unger M, Lee G. Surface composition of spray-dried particles of bovine serum albumin/trehalose/surfactant. Pharm. Res. 17(7), 863-870 (2000). (Pubitemid 30666969)
115. Johnson KA. Preparation of peptide and protein powders for inhalation. Adv. Drug Deliv. Rev. 26(1), 3-15 (1997). (Pubitemid 27288480)
116. Chemistry, Manufacturing and Controls Documentation. FDA Guidance for Industry: Metered dose inhaler (MDI) and dry powder inhaler (DPI) drug products. US Dept of Health and Human Sciences, FDA Center for Drug Evaluation and Research (CDER). (1998).
117. Whitehead K, Karr N, Mitragotri S. Discovery of synergistic permeation enhancers for oral drug delivery. J. Control. Release 128(2), 128-133 (2008). Investigation of various combinations of permeation enhancers and discovery of synergism in several cases.